ClinicalTrials.gg
CompletedNCT02425826UNVEILUpdated Jun 5, 2023Results posted

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

A Phase 4 interventional study of Apremilast and Placebo in Parapsoriasis, sponsored by Amgen. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.

Read the detailed description

This is a Phase 4, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast in subjects with moderate plaque psoriasis. 221 participants were randomized 2 (apremilast):1 (placebo) at approximately 25 sites in the United States. Those randomized to the apremilast treatment group received apremilast 30 mg tablets orally twice daily for 52 weeks. Those randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally twice daily (BID) for 16 weeks. Beginning Week 16, those initially randomized to placebo were switched to receive apremilast 30 mg BID for an additional 36 weeks (52 weeks total).

Study enrolled adult patients with stable moderate plaque psoriasis, who are naïve to systemic psoriasis treatments.

02

Conditions studied

  • Parapsoriasis

Keywords

  • Parapsoriasis
  • Plaque Psoriasis
  • CC-10004
  • Apremilast
  • Moderate Plaque Psoriasis
  • Safety
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, ≥ 18 years of age at the time of signing the document.
  2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Diagnosis of chronic plaque psoriasis for at least 6 months prior to signing the informed consent.
  5. Have moderate plaque psoriasis at screening and baseline as defined by

    1. BSA (Body Surface Area)5% to 10% and
    2. sPGA (Physician's Global Assessment) 3 (moderate) based on a 0 to 5 point scale
  6. Must be in general good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, and clinical laboratories.
  7. No prior exposure to systemic treatments or biologics for the treatment of psoriatic arthritis, psoriasis, or any other indication that could impact the assessment of psoriasis.
  8. Females of (FCBP)must have a negative pregnancy test at Screening and Baseline. While on product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved § options described below: Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
  9. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on investigational product and for at least 28 days after the last dose of investigational product

Exclusion criteria

Exclusion Criteria:

  1. Other than psoriasis, any (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic,immunologic disease, or other major disease that is currently uncontrolled.
  2. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
  3. Any condition, including other inflammatory diseases or dermatologic conditions, which confounds the ability to interpret data from the study, including other types of psoriasis (ie, erythrodermic, guttate, inverse, or pustular psoriasis), other than plaque psoriasis.
  4. Prior history of suicide attempt at any time in the subject's life time prior to signing the and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
  5. Pregnant or breast feeding.
  6. Active substance abuse or a history of substance abuse within 6 months prior to signing the informed consent.
  7. or history of malignancy, except for:

    1. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas;
    2. treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no evidence of recurrence within 5 years of signing the informed consent.
  8. Topical therapy within 2 weeks of randomization (including, but not limited to, topical , retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol). Use of phototherapy within 4 weeks prior to randomization.
  9. Use of any drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
  10. Prolonged sun exposure or use of tanning booths, which may confound the ability to interpret data from the study.
  11. Prior treatment with apremilast.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Apremilast

    Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.

    Drug: Apremilast · Drug: Placebo · Drug: Placebo-Apremilast

  • Placebo comparator
    Placebo

    Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)

    Drug: Placebo · Drug: Placebo-Apremilast

Interventions

  • Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.

    Also known as: CC-10004, Otzela

  • DrugPlacebo

    Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.

  • DrugPlacebo-Apremilast

    At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)

    Also known as: Otezla, CC-10004

06

What researchers measure

Primary outcomes

  1. Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16

    BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score. The range of BSA\*sPGA mean percentage change from baseline to week 16 (end of phase) were -100 to 344.4 and -100 to 100 for the placebo and apremilast groups respectively. Higher scores represented worse outcomes.

    Time frame: Baseline to Week 16 (end of phase)

Secondary outcomes

  1. Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16

    DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

    Time frame: Baseline to Week 16 (end of phase)

  2. Percentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 6-point scale, ranging from 0 (clear) to 5 (very severe), with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are averaged and rounded to the nearest whole number to result in the final sPGA score.

    Time frame: Baseline to Week 16 (end of phase)

  3. Percentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline

    The PtGA response rate is defined as the percentage of participants achieving 0 (clear) or 1 (very mild) on the PtGA scale at Week 16. The PtGA is the assessment by the participant of the overall disease severity at the time of evaluation. The PtGA is a 5-point scale ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to Week 16 (end of phase)

  4. Mean Change From Baseline in Pruritus Visual Analog Scale (VAS)

    The Pruritus VAS assessment was conducted at the baseline visit and each post-baseline visit. The participant was asked to place a vertical stroke on a 100 mm VAS on which the left-hand boundary (0) represents no itch, and the right-hand boundary (100) represents itch as severe as can be imagined. The distance from the mark to the left-hand boundary will be recorded. The Pruritus VAS score ranges from 0 to 100. Higher scores correspond to more severe symptom.

    Time frame: Baseline to Weeks 1 and 16 (end of phase)

  5. Percentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16.

    The ScPGA assessed scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment. Scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA was restricted to the participants with scalp involvement at baseline.

    Time frame: Baseline to Week 16 (end of phase)

  6. Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 16

    The TSQM version II is an 11-question self-administered instrument to understand a participation's satisfaction with the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score mean indicates higher satisfaction with treatment.

    Time frame: Baseline to Week 16 (end of phase)

  7. Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 52

    The TSQM version II is an 11-question self-administered instrument to understand a participants satisfaction on the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.

    Time frame: Baseline to week 52

  8. Mean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16

    The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

    Time frame: Baseline to Week 16 (end of phase)

  9. Percentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16.

    The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

    Time frame: Baseline to Week 16 (end of phase)

  10. Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 16

    The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

    Time frame: Baseline to Week 16 (end of phase)

  11. Mean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52

    BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score.

    Time frame: Baseline to Week 52

  12. Percentage of Participants With Scalp Psoriasis Who Were Initially Randomized to Apremilast and Maintained the Scalp Physician's Global Assessment (ScPGA) Response From Week 16 to Week 52.

    The ScPGA will assess scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment with scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA is restricted to the participants with scalp involvement at baseline.

    Time frame: Week 16 to Week 52

  13. Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase

    Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: From first dose of study drug to Week 16; maximum duration of exposure was 20.1 weeks during placebo controlled phase

  14. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the Apremilast-Exposure Phase

    Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Date of first dose of apremilast during the placebo controlled phase or date of first dose of apremilast after week 16; overall maximum duration of exposure was 61.5 weeks during apremilast-exposure phase

07

Results

Posted Jun 6, 2017

Participant flow

Participants enrolled into this study were those with moderate plaque psoriasis without prior treatment with systemic agents or biologics and were enrolled across 25 study centers in the United States.

Placebo-controlled Phase (Week 0 - 16)
Participant flow — Placebo-controlled Phase (Week 0 - 16)
MilestoneApremilastPlaceboPlacebo-Apremilast
Started148730
Intent to treat147730
Completed121640
Not completed2790
Withdrew: Adverse event520
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject910
Withdrew: Lost to follow-up1040
Withdrew: Other310
Apremilast Extension Phase (Weeks 16-52)
Participant flow — Apremilast Extension Phase (Weeks 16-52)
MilestoneApremilastPlaceboPlacebo-Apremilast
Started121064
Received treatment121064
Completed86050
Not completed35014
Withdrew: Adverse event702
Withdrew: Lost to follow-up806
Withdrew: Withdrawal by subject1204
Withdrew: Lack of efficacy801
Withdrew: Miscellaneous001
Post-Treatment Observational Follow-Up
Participant flow — Post-Treatment Observational Follow-Up
MilestoneApremilastPlaceboPlacebo-Apremilast
Started81049
Completed80049
Not completed100

Outcome measures

PrimaryMean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16

BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score. The range of BSA\*sPGA mean percentage change from baseline to week 16 (end of phase) were -100 to 344.4 and -100 to 100 for the placebo and apremilast groups respectively. Higher scores represented worse outcomes.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Mean · percentage change
Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16
percentage changePlaceboApremilast
Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16-10.17 ± 64.043-48.07 ± 43.699
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = <0.0001 · Ls mean difference: -39.84 · 95% CI -54.39 to -25.30Based on 2-way ANCOVA with treatment and site as factors and baseline value as covariate.
SecondaryMean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16

DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Mean · units on a scale
Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
units on a scalePlaceboApremilast
Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16-2.4 ± 6.62-4.8 ± 5.80
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = 0.0008 · Ls mean difference: -2.5 · 95% CI -3.9 to -1.0Based on 2-way ANCOVA with treatment and site as factors and baseline value as covariate.
SecondaryPercentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 6-point scale, ranging from 0 (clear) to 5 (very severe), with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are averaged and rounded to the nearest whole number to result in the final sPGA score.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline9.6 (4.7 to 18.5)30.4 (23.6 to 38.2)
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test stratified by sites.) · Difference: 21.0 · 95% CI 11.0 to 31.1Two-sided 95% confidence intervals (CI) is based on normal approximation
SecondaryPercentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline

The PtGA response rate is defined as the percentage of participants achieving 0 (clear) or 1 (very mild) on the PtGA scale at Week 16. The PtGA is the assessment by the participant of the overall disease severity at the time of evaluation. The PtGA is a 5-point scale ranging from 0 (clear) to 4 (severe).

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline20.5 (12.9 to 31.2)33.8 (26.7 to 41.7)
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0365 · Difference: 13.7 · 95% CI 1.7 to 25.7Two-sided 95% CI is based on normal approximation
SecondaryMean Change From Baseline in Pruritus Visual Analog Scale (VAS)

The Pruritus VAS assessment was conducted at the baseline visit and each post-baseline visit. The participant was asked to place a vertical stroke on a 100 mm VAS on which the left-hand boundary (0) represents no itch, and the right-hand boundary (100) represents itch as severe as can be imagined. The distance from the mark to the left-hand boundary will be recorded. The Pruritus VAS score ranges from 0 to 100. Higher scores correspond to more severe symptom.

Time frame:
Baseline to Weeks 1 and 16 (end of phase)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Pruritus Visual Analog Scale (VAS)
units on a scalePlaceboApremilast
Week 1-9.6 ± 21.50-13.9 ± 20.00
Week 16-10.2 ± 30.73-19.2 ± 26.09
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = 0.0016 · Ls mean difference: -11.6 · 95% CI -18.8 to -4.5Based on 2-way ANCOVA with treatment and site as factors and baseline value as covariate.
SecondaryPercentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16.

The ScPGA assessed scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment. Scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA was restricted to the participants with scalp involvement at baseline.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Number · percentage of participants
Percentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16.
percentage of participantsPlaceboApremilast
Percentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16.38.2 (26.5 to 51.4)50.0 (40.9 to 59.1)
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0463 · Difference: 11.8 · 95% CI -4.0 to 27.6Two-sided 95% CI is based on normal approximation.
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 16

The TSQM version II is an 11-question self-administered instrument to understand a participation's satisfaction with the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score mean indicates higher satisfaction with treatment.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 16
units on a scalePlaceboApremilast
TSQM-Effectiveness38.81 ± 25.84357.25 ± 26.484
TSQM-Side Effects75.00 ± 32.42878.50 ± 20.858
TSQM-Convenience65.68 ± 16.65066.93 ± 21.216
TSQM-Global Satisfaction48.74 ± 25.67363.24 ± 23.624
Statistical analysis
  • Placebo vs Apremilast · ANOVA · p = <0.0001 · Ls mean difference: 17.80 · 95% CI 10.36 to 25.24Based on 2-way ANOVA with treatment and site as factors.
  • Placebo vs Apremilast · ANOVA · p = 0.3433 · Ls mean difference: 5.00 · 95% CI -5.40 to 15.40Based on 2-way ANOVA with treatment and site as factors.
  • Placebo vs Apremilast · ANOVA · p = 0.6250 · Ls mean difference: 1.40 · 95% CI -4.25 to 7.06Based on 2-way ANOVA with treatment and site as factors.
  • Placebo vs Apremilast · ANOVA · p = <0.0001 · Mean difference (final values): 14.07 · 95% CI 7.16 to 20.97
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 52

The TSQM version II is an 11-question self-administered instrument to understand a participants satisfaction on the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.

Time frame:
Baseline to week 52
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 52
units on a scalePlacebo-ApremilastApremilast
TSQM-Effectiveness57.68 ± 26.87954.13 ± 26.898
TSQM-Side Effects77.29 ± 27.54175.45 ± 24.904
TSQM-Convenience72.74 ± 17.22271.76 ± 19.359
TSQM-Global Satisfaction59.24 ± 27.94159.92 ± 27.053
SecondaryMean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16

The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Mean · percentage change
Mean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16
percentage changePlaceboApremilast
Mean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16-3.87 ± 79.441-40.72 ± 49.523
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = <0.0001 · Ls mean difference: -37.0 · 95% CI -54.08 to -19.91Based on 2-way ANCOVA with treatment and site as factors and baseline value as covariate
SecondaryPercentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16.

The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16.
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16.24.7 (16.2 to 35.6)53.4 (45.4 to 61.2)
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Difference: 29.1 · 95% CI 16.3 to 41.8Two-sided 95% CI is based on normal approximation
SecondaryPercentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 16

The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

Time frame:
Baseline to Week 16 (end of phase)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 16
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 168.2 (3.8 to 16.8)21.6 (15.8 to 28.9)
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0136 · Difference: 13.5 · 95% CI 4.4 to 22.72-sided 95% CI is based on normal approximation.
SecondaryMean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52

BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score.

Time frame:
Baseline to Week 52
Reported as:
Mean · percentage change
Mean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52
percentage changePlacebo-ApremilastApremilast
Mean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52-42.23 ± 93.211-55.45 ± 44.619
SecondaryPercentage of Participants With Scalp Psoriasis Who Were Initially Randomized to Apremilast and Maintained the Scalp Physician's Global Assessment (ScPGA) Response From Week 16 to Week 52.

The ScPGA will assess scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment with scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA is restricted to the participants with scalp involvement at baseline.

Time frame:
Week 16 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Scalp Psoriasis Who Were Initially Randomized to Apremilast and Maintained the Scalp Physician's Global Assessment (ScPGA) Response From Week 16 to Week 52.
percentage of participantsApremilast
Responder status at Week 1650.0 (40.9 to 59.1)
Responder status maintained at Week 5280.4 (68.2 to 88.7)
SecondaryNumber of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase

Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
From first dose of study drug to Week 16; maximum duration of exposure was 20.1 weeks during placebo controlled phase
Reported as:
Number · participants
Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
participantsPlaceboApremilast
≥ At Least 1 TEAE3592
≥ 1 Drug-related TEAE2171
≥ At Least 1 Severe TEAE13
≥ At Least 1 Serious TEAE03
≥ 1 Serious Drug-related TEAE00
≥ 1 TEAE leading to drug withdrawal35
≥ 1 TEAE Leading to drug interruption39
Any TEAE leading to death00
SecondaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the Apremilast-Exposure Phase

Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Date of first dose of apremilast during the placebo controlled phase or date of first dose of apremilast after week 16; overall maximum duration of exposure was 61.5 weeks during apremilast-exposure phase
Reported as:
Number · participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the Apremilast-Exposure Phase
participantsApremilast
≥ At Least 1 TEAE142
≥ 1 Drug-related TEAE98
≥ At Least 1 Severe TEAE5
≥ At Least 1 Serious TEAE10
≥ 1 Serious Drug-related TEAE1
≥ 1 TEAE leading to drug withdrawal14
≥ 1 TEAE Leading to drug interruption27
Any TEAE leading to death0

Adverse events

Collected over Adverse events are reported for the 16-week PBO-controlled and the apremilast extension phase and monitored from the date of the first dose of apremilast to 12 January2017; maximum duration of exposure was 61.5 weeks during apremilast-exposure phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Phase: Apremilast (Weeks 0-16)—3/147 (2%)73/147 (49.7%)
Placebo-Controlled Phase: Placebo (Weeks 0-16)—0/73 (0%)23/73 (31.5%)
Extension Phase: APR/APR and Placebo/APR (Weeks 0-52)—10/211 (4.7%)101/211 (47.9%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo-Controlled Phase: Apremilast (Weeks 0-16)Placebo-Controlled Phase: Placebo (Weeks 0-16)Extension Phase: APR/APR and Placebo/APR (Weeks 0-52)
CholelithiasisHepatobiliary disorders1/1470/731/211
PyelonephritisInfections and infestations1/1470/731/211
Cerebrovascular accidentNervous system disorders1/1470/731/211
NephrolithiasisRenal and urinary disorders1/1470/731/211
DiverticulitisInfections and infestations0/1470/731/211
PneumoniaInfections and infestations0/1470/731/211
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1470/731/211
KeratoacanthomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1470/731/211
DizzinessNervous system disorders0/1470/731/211
Suicide attemptPsychiatric disorders0/1470/731/211
Most frequent other events
Most frequent other events
EventPlacebo-Controlled Phase: Apremilast (Weeks 0-16)Placebo-Controlled Phase: Placebo (Weeks 0-16)Extension Phase: APR/APR and Placebo/APR (Weeks 0-52)
DiarrhoeaGastrointestinal disorders43/14712/7359/211
HeadacheNervous system disorders30/1478/7332/211
NauseaGastrointestinal disorders26/1477/7340/211
NasopharyngitisInfections and infestations5/1472/7322/211
Upper respiratory tract infectionInfections and infestations10/1473/7315/211
VomitingGastrointestinal disorders9/1472/7312/211
Decreased appetiteMetabolism and nutrition disorders6/1474/7311/211

Baseline characteristics

The intent to treat (ITT) population consisted all participants who were randomized. Participants were included in the treatment arm which they were randomized into the ITT population.

Age, Categorical
Age, Categorical(Participants)PlaceboApremilastTotal
<=18 years000
Between 18 and 65 years60120180
>=65 years132841
Age, Continuous
Age, Continuous(years)PlaceboApremilastTotal
Mean51.1 ± 13.7448.6 ± 15.4149.4 ± 14.89
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilastTotal
Female3274106
Male4174115
Body Surface Area (BSA)
Body Surface Area (BSA)(percent affected)PlaceboApremilastTotal
Mean7.1 ± 1.757.2 ± 1.617.2 ± 1.66
Static Physician's Global Assessment (sPGA) Score
Static Physician's Global Assessment (sPGA) Score(Participants)PlaceboApremilastTotal
1 = Almost Clear000
2 = Mild000
3 = Moderate70144214
4 =Severe336
5 = Very Severe000
Missing011
Product of BSA and sPGA
Product of BSA and sPGA(psoriasis severity index)PlaceboApremilastTotal
Mean21.6 ± 5.8721.8 ± 5.1721.7 ± 5.40
Duration of Psoriasis
Duration of Psoriasis(years)PlaceboApremilastTotal
Mean12.85 ± 12.35017.02 ± 14.13815.64 ± 13.684
Ethnicity
Ethnicity(participants)PlaceboApremilastTotal
Hispanic or Latino41317
Not Hispanic or Latino69134203
Unknown011
08

Study locations

26 sites
  • UAB at Birmingham - The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • Center For Dermatology
    Fremont, California 94538, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Blue Harbor Dermatology
    Newport Beach, California 92663, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • East Bay Rheumatology Medical
    San Leandro, California 94578, United States
  • Tien Q. Nguyen MD Inc
    Tustin, California 92780, United States
  • UConn Health Center
    Farmington, Connecticut 06030, United States
  • Dermatology Associates
    Panama City, Florida 32405-4542, United States
  • USF Health Faculty Office Building-FOB
    Tampa, Florida 33612, United States
  • Forward Clinical Trials Inc
    Tampa, Florida 33624, United States
  • Dermatologic Surgery Specialists, P.C.
    Macon, Georgia 31217, United States
  • Shideler Clinical Research Center
    Carmel, Indiana 46032, United States
  • Dermatology Specialists, PSC
    Louisville, Kentucky 40202, United States
  • DermResearch, PLLC
    Louisville, Kentucky 40217, United States
  • Lawrence Green, MD, LLC
    Rockville, Maryland 20850, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Las Vegas Skin and Cancer Clinics
    Las Vegas, Nevada 89052, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Garden City Dermatology
    Garden City, New York 11530, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Dermatology Associates of Rochester PC
    Rochester, New York 14623, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0501, United States
  • Dermatology and Laser Center of Charleston
    Charleston, South Carolina 29414, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84132, United States
  • Dermatology Consultants, Inc.
    Lynchburg, Virginia 24501, United States
09

References and documents

Publications

  • Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2409-2414. doi: 10.1111/jdv.17520. Epub 2021 Aug 23. PubMed 34255891 ↗
  • Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. J Drugs Dermatol. 2018 Feb 1;17(2):221-228. PubMed 29462231 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Feb 2016, 9 months.

Results were first posted in Jun 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2015
First posted
Apr 24, 2015
StartActual
Apr 20, 2015
Primary completionActual
Feb 12, 2016
CompletionActual
Nov 22, 2016
Results first posted
Jun 6, 2017
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02425826
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 24, 2015
Start date
Apr 20, 2015
Primary completion
Feb 12, 2016
Completion
Nov 22, 2016
Results posted
Jun 6, 2017
Last update
Jun 5, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion